Impact of pharmaceutical care integrated at a psychosocial intervention to reduce caregiver's burden in Alzheimer's disease or related dementias: Negative results at 18 months and difficulties to conduct PHARMAID RCT. - Université de Lille Accéder directement au contenu
Article Dans Une Revue Contemporary Clinical Trials Communications Année : 2023

Impact of pharmaceutical care integrated at a psychosocial intervention to reduce caregiver's burden in Alzheimer's disease or related dementias: Negative results at 18 months and difficulties to conduct PHARMAID RCT.

T. Novais
  • Fonction : Auteur
S. Qassemi
  • Fonction : Auteur
P. Cestac
  • Fonction : Auteur
C. Mccambridge
  • Fonction : Auteur
H. Villars
  • Fonction : Auteur
A. Zueras
  • Fonction : Auteur
M. Dambrine
  • Fonction : Auteur
D. Huvent-Grelle
  • Fonction : Auteur
J. Roche
  • Fonction : Auteur
S. Schoenenburg
  • Fonction : Auteur
D. Federico
  • Fonction : Auteur
A. C. Nier
  • Fonction : Auteur
P. Krolak-Salmon
  • Fonction : Auteur
C. Mouchoux
  • Fonction : Auteur
  • PersonId : 920050

Résumé

Background Psychosocial interventions for caregivers of patients with Alzheimer disease and relative dementias (ADRD) reported a caregiver burden improvement. Multicomponent intervention integrating pharmaceutical care has not yet been evaluated while ADRD patients and their caregivers are exposed to high risk of drug-related problems. The PHARMAID study aimed to assess the impact of personalized pharmaceutical care integrated to a psychosocial program on the burden of ADRD caregivers at 18 months. Methods The PHARMAID RCT was conducted between September 2016 and June 2020 [ClinicalTrials.gov: NCT02802371 ]. PHARMAID study planned to enroll 240 dyads, i.e. ADRD patients and caregivers, whose inclusion criteria were: outpatient with mild or major neurocognitive disorders due to ADRD, living at home, receiving support from a family caregiver. Three parallel groups compared a control group with two interventional groups: psychosocial intervention and integrated pharmaceutical care at a psychosocial intervention. The main outcome was the caregiver burden assessed by the Zarit Burden Index (ZBI, score range 0–88) at 18 months. Results Overall, 77 dyads were included (32% of the expected sample size). At 18 months, the mean ZBI scores were 36.7 ± 16.8 in the control group, 30.3 ± 16.3 for the group with psychosocial intervention, and 28.8 ± 14.1 in group with integrated pharmaceutical care at psychosocial intervention. No significant difference was demonstrated between the three groups (p = 0.326). Conclusions The findings suggest that PHARMAID program had no significant impact on caregiver burden at 18 months. Several limitations have been highlighted and discussed by the authors in order to formulate recommendations for further research.
Fichier principal
Vignette du fichier
1-s2.0-S2451865423000923-main.pdf (978.85 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04575626 , version 1 (15-05-2024)

Licence

Identifiants

Citer

T. Novais, S. Qassemi, P. Cestac, C. Mccambridge, H. Villars, et al.. Impact of pharmaceutical care integrated at a psychosocial intervention to reduce caregiver's burden in Alzheimer's disease or related dementias: Negative results at 18 months and difficulties to conduct PHARMAID RCT.. Contemporary Clinical Trials Communications, 2023, Contemporary Clinical Trials Communications, 33, pp.101146. ⟨10.1016/j.conctc.2023.101146⟩. ⟨hal-04575626⟩

Collections

UNIV-LILLE
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More